- Nivolumab plus chemotherapy or ipilimumab in the first-line palliative therapy of esophageal, gastroesophageal junction, and gastric cancer2023 | Faculty of Medicine in Hradec Králové
- Tumor regression grading after neoadjuvant treatment of esophageal and gastroesophageal junction adenocarcinoma: results of an international Delphi consensus survey2021 | Faculty of Medicine in Hradec Králové
- The value of 18F-FDG-PET testing in the management of esophageal and gastroesophageal junction adenocarcinoma - review2021 | First Faculty of Medicine